Sanofi Broadens Portfolio By Licensing A Monoclonal Antibody From Merrimack
Privately held Merrimack gets $60 million upfront for MM-121, a monoclonal antibody in Phase I/II.
Privately held Merrimack gets $60 million upfront for MM-121, a monoclonal antibody in Phase I/II.